445 related articles for article (PubMed ID: 33134160)
1. M6A RNA Methylation Regulator HNRNPC Contributes to Tumorigenesis and Predicts Prognosis in Glioblastoma Multiforme.
Wang LC; Chen SH; Shen XL; Li DC; Liu HY; Ji YL; Li M; Yu K; Yang H; Chen JJ; Qin CZ; Luo MM; Lin QX; Lv QL
Front Oncol; 2020; 10():536875. PubMed ID: 33134160
[TBL] [Abstract][Full Text] [Related]
2. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
3. m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
Li F; Wang H; Huang H; Zhang L; Wang D; Wan Y
Front Genet; 2020; 11():994. PubMed ID: 33193582
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
Liu T; Li C; Jin L; Li C; Wang L
Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961
[TBL] [Abstract][Full Text] [Related]
6. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
7. Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma.
Du J; Hou K; Mi S; Ji H; Ma S; Ba Y; Hu S; Xie R; Chen L
Front Oncol; 2020; 10():208. PubMed ID: 32211315
[TBL] [Abstract][Full Text] [Related]
8. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
9. N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
Zhao Z; Cai Q; Zhang P; He B; Peng X; Tu G; Peng W; Wang L; Yu F; Wang X
Front Mol Biosci; 2021; 8():657087. PubMed ID: 34179079
[TBL] [Abstract][Full Text] [Related]
10. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
Qi LW; Jia JH; Jiang CH; Hu JM
Front Genet; 2020; 11():614566. PubMed ID: 33519919
[TBL] [Abstract][Full Text] [Related]
11. A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms.
Chen X; Mo S; Zong L; Yu S; Lu Z; Chen J
Neuroendocrinology; 2022; 112(12):1187-1199. PubMed ID: 35609514
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a m
Zhao X; Cui L
Am J Cancer Res; 2019; 9(10):2156-2169. PubMed ID: 31720080
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an m6A RNA Methylation Regulator-Based Signature for Prognostic Prediction in Cervical Squamous Cell Carcinoma.
Pan J; Xu L; Pan H
Front Oncol; 2020; 10():1444. PubMed ID: 32974164
[No Abstract] [Full Text] [Related]
14. Identification of m6A methyltransferase-related genes predicts prognosis and immune infiltrates in head and neck squamous cell carcinoma.
Zhang Y; Li L; Ye Z; Zhang L; Yao N; Gai L
Ann Transl Med; 2021 Oct; 9(20):1554. PubMed ID: 34790760
[TBL] [Abstract][Full Text] [Related]
15. Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression.
Lv W; Tan Y; Xiong M; Zhao C; Wang Y; Wu M; Wu Y; Zhang Q
J Transl Med; 2021 Dec; 19(1):527. PubMed ID: 34952600
[TBL] [Abstract][Full Text] [Related]
16. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic, progressive and prognostic performance of m
Zhuang Z; Chen L; Mao Y; Zheng Q; Li H; Huang Y; Hu Z; Jin Y
Int J Biol Sci; 2020; 16(11):1785-1797. PubMed ID: 32398949
[No Abstract] [Full Text] [Related]
18. Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Li R; Yin YH; Ji XL; Liu X; Li JP; Qu YQ
Front Mol Biosci; 2021; 8():644620. PubMed ID: 34150845
[TBL] [Abstract][Full Text] [Related]
19. m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.
Cong R; Ji C; Zhang J; Zhang Q; Zhou X; Yao L; Luan J; Meng X; Song N
Transl Androl Urol; 2021 Feb; 10(2):662-679. PubMed ID: 33718069
[TBL] [Abstract][Full Text] [Related]
20. The methylation modification of m6A regulators contributes to the prognosis of head and neck squamous cell carcinoma.
Chen Y; Jiang X; Li X; Yan D; Liu J; Yang J; Yan S
Ann Transl Med; 2021 Aug; 9(16):1346. PubMed ID: 34532483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
